Interacting Drugs |
Paclitaxel (nanoparticle albumin bound) vs Denosumab |
Security Level |
 |
Mechanism |
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. |
Management |
Monitor therapy |
Paclitaxel (nanoparticle albumin bound) vs Denosumab
Post Review about Paclitaxel (nanoparticle albumin bound) vs Denosumab Click here to cancel reply.
Other Interactions of Paclitaxel (nanoparticle albumin bound)
Other Interactions of Denosumab
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.